BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals (NASDAQ: NPSP), a specialty pharmaceutical company focused on developing therapeutics for rare gastrointestinal and endocrine disorders, today announced it has begun patient enrollment in a Phase 3 registration study, known as REPLACE, evaluating NPSP558 for the treatment of adults with hypoparathyroidism. NPSP558 is the company’s proprietary recombinant full-length human parathyroid hormone (PTH 1-84), which mimics the action of natural parathyroid hormone. Hypoparathyroidism is a rare condition in which the body produces insufficient levels of parathyroid hormone causing lower than normal levels of calcium in the blood, known as hypocalcemia. There is currently no approved replacement therapy for hypoparathyroidism. NPS believes positive results from REPLACE will enable it to seek U.S. marketing approval for NPSP558 for the treatment of hypoparathyroidism.
